Atea, riding interest in COVID-19 drugs, pulls off one of 2020's top biotech IPOs

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Oct 30, 2020 at 10:52: AM
via Boston biotech Atea Pharmaceuticals, a developer of small molecule drugs for infectious diseases, has raised $300 million in an initial public offering, selling 12.5 million shares at $24 apiece.

article source
 




Top Bottom
Back
Quote